{
    "Trade/Device Name(s)": [
        "GEM Hemochron 100 System",
        "GEM Hemochron 100 Activated Clotting Time Plus Test (ACT+)",
        "GEM Hemochron 100 Low Range Activated Clotting Time Test (ACT-LR)",
        "directCHECK ACT+ Whole Blood Control, Level 1 and Level 2",
        "directCHECK ACT-LR Whole Blood Control, Level 1 and Level 2"
    ],
    "Submitter Information": "Accriva Diagnostics, Inc.",
    "510(k) Number": "K202101",
    "Predicate Device Reference 510(k) Number(s)": [
        "K193041",
        "K941007",
        "K960749",
        "K120977"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JPA",
        "JBP",
        "GGN"
    ],
    "Summary Letter Date": "July 28, 2020",
    "Summary Letter Received Date": "July 29, 2020",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.5425",
        "21 CFR 864.7140"
    ],
    "Regulation Name(s)": [
        "Multipurpose system for in vitro coagulation studies",
        "Activated whole blood clotting time tests"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "Activated Clotting Time (ACT+)",
        "Low Range Activated Clotting Time (ACT-LR)"
    ],
    "Specimen Type(s)": [
        "Fresh Whole Blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "GEM Hemochron 100 System",
        "Hemochron Signature Series"
    ],
    "Method(s)/Technology(ies)": [
        "Mechanical-optical clot detection",
        "Disposable test cartridges with dried activators"
    ],
    "Methodologies": [
        "Quantitative whole blood clotting time assay"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Assay",
        "Control",
        "Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for GEM Hemochron 100 System and associated ACT+/ACT-LR assays and controls for quantitative measurement of whole blood clotting time at point-of-care settings.",
    "Indications for Use Summary": "Quantitative monitoring of anticoagulation with unfractionated heparin in adult patients during cardiovascular surgery, cardiac ablation, extracorporeal life support, and cardiology procedures using fresh whole blood at point-of-care; quality control assays for in vitro diagnostic use.",
    "fda_folder": "Hematology"
}